Blog | HemaCare

Treatment with Mesoblast’s Remestemcel-L Leads to an 83% Survival Rate in Patients with ARDS

Jun 2, 2020 10:03:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Stem Cells


COVID-19 patients dependent on ventilators showed promising results when treated with new drug in New York’s Mt. Sinai hospital.

The U.S Food and Drug Administration approved Mesoblast’s Investigational New Drug (IND) application to treat patients with COVID-19−related Acute Respiratory Distress Syndrome (ARDS) using remestemcel-L, an intravenous (IV) infusion of allogeneic mesenchymal stem cells (MSCs).

Read More

Possible New Improvements for Acute Myeloid Leukemia Treatment

May 26, 2020 10:02:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer, Blood Disorders


Researchers continue to build on success of treating AML patients with an alkaloid (HHT) derived from a conifer tree.

Acute myeloid leukemia (AML) is not one disease but a group of hematopoietic neoplasms with varying genotypes, yet similar phenotypes. The cancer arises from hematopoietic stem cells that normally differentiate into myeloid cells such as granulocytes, monocytes, and erythrocytes.

Read More

BCMA CAR T Cells Response in Myeloma Improved by Gamma Secretase Inhibitor

May 19, 2020 12:09:00 PM / by Stacy Matthews Branch, DVM, PhD


A clinical trial targeting BCMA CAR-T cells with GSIs shows promising results for patients suffering from multiple myeloma.

Multiple myeloma (MM) is a plasma cell cancer that has affected an estimated 32,110 people in the US in 2019 according to the National Cancer Institute. About a half million people worldwide have this disease. Due to the progressive and mutational nature of MM, it remains difficult to treat successfully. Studies to better understand the mechanisms involved in MM progression are needed to inform what therapeutic approaches would best provide effective treatment for MM.

Read More

Could Stem Cell Therapy Be the Better Treatment for MS?

May 12, 2020 10:08:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Autoimmune Disorders, Stem Cell Therapy, Stem Cells


A Phase III clinical trial comparing hematopoietic stem cell transplants to immunomodulators is underway.

Multiple sclerosis (MS) is an autoimmune disease characterized by the destruction of the myelin sheath of nerve fibers. There is no cure for the condition, but there are a number of FDA-approved immunomodulators or disease-modifying therapies to reduce relapses and slow disease progression. Despite the availability of these drugs, their varying efficacy, adverse effects, and expense are significant concerns. Therefore, a means to safely and effectively control MS symptoms and progression is still under investigation.

Read More

FDA Grants New Therapy for Sickle Cell Treatment

May 5, 2020 10:05:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Gene Therapy, Cell Therapy, Stem Cells


A newly developed single-treatment approach, uses autologous gene therapy and CD34 stem cells to improve erythrocyte function in SSD patients.

Sickle cell disease (SSD) refers to a group of inherited erythrocyte disorders. Hemoglobin in people with SSD becomes defective leading to abnormal shaping of erythrocytes. The defective hemoglobin form, hemoglobin S, replaces the normal hemoglobin A. The abnormally crescent or sickle-shaped erythrocytes cause a number of illnesses associated with the clogging of vessels, poor oxygen flow to organs, and associated damage.

Read More

      Subscribe Here!

      Posts by Topic

      see all

      Recent Posts